Payment overview · 2025
General Payments
$1,995.50
28 reported records · 15 companies
Healthcare provider profile · identity verified
Asif Shah, DPM
Podiatric Medicine & Surgery Service Providers|Podiatrist|Foot Surgery · GLEN ALLEN, VA · NPI 1669418786
Verified facts
What the public records show
CMS Open Payments records show Asif Shah, DPM received $1,995.50 in general payments during 2025 across 28 reported records.
ConvaTec Inc. accounted for 46.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Krystexxa.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported KRYSTEXXA as an associated drug or biological on 45998 records involving 14548 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Krystexxa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ConvaTec Inc. | Unresolved — no canonical attribution shown | $927.26 | 46.5% | 6 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $398.09 | 19.9% | 3 | 2025 |
| Integra LifeSciences Corporation | Unresolved — no canonical attribution shown | $154.60 | 7.8% | 2 | 2025 |
| Linvatec Corporation | Unresolved — no canonical attribution shown | $152.10 | 7.6% | 2 | 2025 |
| Fortis Surgical, LLC | Unresolved — no canonical attribution shown | $94.13 | 4.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $59.59 | 3.0% | 3 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $42.05 | 2.1% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.02 | 1.9% | 2 | 2025 |
| SPR Therapeutics, Inc | Unresolved — no canonical attribution shown | $30.63 | 1.5% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$29.90 | 1.5% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $22.21 | 1.1% | 1 | 2025 |
| Urgo Medical North America, LLC | Unresolved — no canonical attribution shown | $14.52 | 0.7% | 1 | 2025 |
| AXOGEN | Unresolved — no canonical attribution shown | $14.36 | 0.7% | 1 | 2025 |
| Reprise Biomedical, Inc. | Unresolved — no canonical attribution shown | $12.89 | 0.7% | 1 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $6.15 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,435.24 | 27 |
| Travel and Lodging | $560.26 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INNOVAMATRIX AC Normalized: innovamatrix ac |
Device | ConvaTec Inc. | $927.26 | 6 | 2025 |
Source payment records
|
|||||
| PROPHECY Normalized: prophecy |
Device | Stryker Corporation | $168.42 | 1 | 2025 |
Source payment records
|
|||||
| Integra Normalized: integra |
Device | Integra LifeSciences Corporation | $154.60 | 2 | 2025 |
Source payment records
|
|||||
| Integra Dermal Regeneration Template Normalized: integra dermal regeneration template |
Device | Integra LifeSciences Corporation | $154.60 | 2 | 2025 |
Source payment records
|
|||||
| PRIMATRIX Normalized: primatrix |
Device | Integra LifeSciences Corporation | $154.60 | 2 | 2025 |
Source payment records
|
|||||
| BIOBRACE 23MM Normalized: biobrace 23mm |
Device | Linvatec Corporation | $152.10 | 2 | 2025 |
Source payment records
|
|||||
| HERCULES SUTURE ANCHOR SYSTEM Normalized: hercules suture anchor system |
Device | Linvatec Corporation | $152.10 | 2 | 2025 |
Source payment records
|
|||||
| EASYFUSE Normalized: easyfuse |
Device | Stryker Corporation | $134.69 | 1 | 2025 |
Source payment records
|
|||||
| ORTHOLOC 3DI Normalized: ortholoc 3di |
Device | Stryker Corporation | $134.69 | 1 | 2025 |
Source payment records
|
|||||
| VARIAX Normalized: variax |
Device | Stryker Corporation | $134.69 | 1 | 2025 |
Source payment records
|
|||||
| COLINK 2 Normalized: colink 2 |
Device | Linvatec Corporation | $113.93 | 1 | 2025 |
Source payment records
|
|||||
| IBS Normalized: ibs |
Device | Linvatec Corporation | $113.93 | 1 | 2025 |
Source payment records
|
|||||
| QUANTUM Normalized: quantum |
Device | Linvatec Corporation | $113.93 | 1 | 2025 |
Source payment records
|
|||||
| ANCHORAGE Normalized: anchorage |
Device | Stryker Corporation | $94.98 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $59.59 | 3 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $42.05 | 2 | 2025 |
Source payment records
|
|||||
| ALLOGRAFT TISSUE Normalized: allograft tissue |
Device | Linvatec Corporation | $38.17 | 1 | 2025 |
Source payment records
|
|||||
| HERCULES SYNDESMOSIS IMPLANT SYSTEM Normalized: hercules syndesmosis implant system |
Device | Linvatec Corporation | $38.17 | 1 | 2025 |
Source payment records
|
|||||
| NEOSPAN Normalized: neospan |
Device | Linvatec Corporation | $38.17 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $37.02 | 2 | 2025 |
Source payment records
|
|||||
| SPRINT PNS System Normalized: sprint pns system |
Device | SPR Therapeutics, Inc | $30.63 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $29.90 | 1 | 2025 |
Source payment records
|
|||||
| GRAFIX Normalized: grafix |
Biological | Smith+Nephew, Inc. | $22.21 | 1 | 2025 |
Source payment records
|
|||||
| OASIS Normalized: oasis |
Device | Smith+Nephew, Inc. | $22.21 | 1 | 2025 |
Source payment records
|
|||||
| VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP Normalized: vashe wound solution 250 ml 8 5 fl oz flip top cap |
Device | Urgo Medical North America, LLC | $14.52 | 1 | 2025 |
Source payment records
|
|||||
| Miro3D Normalized: miro3d |
Device | Reprise Biomedical, Inc. | $12.89 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $6.15 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $6.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| KRYSTEXXA krystexxa |
2025 | Krystexxa | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | KRYSTEXXA open payments reported associated product |
CMS Open Payments — General Payments 45998 supporting records · 14548 recipient NPIs · example record 1226871690 |
Krystexxa · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 73 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 67 | 26 |
| Cephalexin | Cephalexin | 48 | 40 |
| Ibuprofen | Ibuprofen | 41 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 31 | suppressed |
| Ketoconazole | Ketoconazole | 29 | 19 |
| Methylprednisolone | Methylprednisolone | 29 | 23 |
| Ciclopirox | Ciclopirox | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 13 |
| Nystatin | Nystatin | 14 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Krystexxa | Pegloticase | 13 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,995.50 · 28 records | ConvaTec Inc. | ALLOGRAFT TISSUE, ANCHORAGE, BIOBRACE 23MM, COLINK 2, EASYFUSE, GRAFIX, HERCULES SUTURE ANCHOR SYSTEM, HERCULES SYNDESMOSIS IMPLANT SYSTEM, IBS, INNOVAMATRIX AC, INTELLIS ADAPTIVESTIM, Integra, Integra Dermal Regeneration Template, JOURNAVX, KRYSTEXXA, Kerecis GraftGuide, Kerecis SurgiClose, Miro3D, NEOSPAN, NUZYRA, OASIS, ORTHOLOC 3DI, PRIMATRIX, PROPHECY, QUANTUM, SPRINT PNS System, VARIAX, VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Krystexxa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error